warnings
WARNINGS Ciclopirox Gel, 0.77% is not for ophthalmic, oral, or intravaginal use. Keep out of reach of children.
CICLOPIROX
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- CICLOPIROX
- Generic name
- CICLOPIROX
- Manufacturer
- Bryant Ranch Prepack
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 808733e7-9402-4f9b-99ce-ca6d04ad4aee
- SPL ID
- 52d76980-71dc-4e9d-aeea-1a101eef6b3c
- Version
- 103
- Effective date
- 2023-06-15
- Source export date
- 2026-10-27
- Source partition
- 12
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-10-27/977776a6cc37ec1c77259da8a93ae161850a3aa120341096e5a03428b84d016b/drug-label-0012-of-0014.json.zip
- Source manifest SHA-256
- 6be3667a3beefe6c0ead4c723ea963050533a2bc725a8044d58b07d18b258c55
- Import run
- 20261027T193451Z
- Imported at
- 2026-10-27 21:01:48
| Harmonized routes |
|---|
| TOPICAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 078266 | derived:openfda.application_number |
| application number | ANDA078266 | openfda.application_number | |
| brand name | CICLOPIROX | openfda.brand_name | |
| generic name | CICLOPIROX | openfda.generic_name | |
| manufacturer name | Bryant Ranch Prepack | openfda.manufacturer_name | |
| ndc | package | 63629-8622-1 | openfda.package_ndc |
| ndc | product | 63629-8622 | openfda.product_ndc |
| ndc11 | package | 63629862201 | derived:openfda.package_ndc |
| rxcui | 313941 | openfda.rxcui | |
| spl id | 52d76980-71dc-4e9d-aeea-1a101eef6b3c | id | |
| spl set id | 808733e7-9402-4f9b-99ce-ca6d04ad4aee | set_id | |
| unii | 19W019ZDRJ | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS In clinical trials, 140 (39%) of 359 subjects treated with Ciclopirox Gel, 0.77% reported adverse experiences, irrespective of relationship to test materials, which resulted in 8 subjects discontinuing treatment. The most frequent experience reported was skin burning sensation upon application, which occurred in approximately 34% of seborrheic dermatitis patients and 7% of tinea pedis patients. Adverse experiences occurring between 1% to 5% were contact dermatitis and pruritus. Other reactions that occurred in less than 1% included dry skin, acne, rash, alopecia, pain upon application, eye pain, and facial edema.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.